EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer
This study will examine whether the new investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause ovarian, fallopian, or peritoneal cancers. Recruitment in the United States is complete but the study is still enrolling in other countries.
Ovarian Neoplasms|Peritoneal Neoplasms|Fallopian Tube Neoplasms
DRUG: epothilone b
Tumor response rate, tumor response was defined by the Response Evaluation Criteria in Solid Tumors (RECIST)., Every 2 cycles
Time to disease progression, from start of treatment to documented disease progression, death from study indication, or the date of last follow-up|Overall survival, measured from the start of treatment to the date of death or the last date the patient was known to be alive.|Duration of response, duration of response in patients with complete response (CR) or partial response (PR), Every 3 months|recording all adverse events (AEs) and serious adverse events (SAEs), Safety and tolerability of patupilone by monitoring and recording all AEs and SAEs, regular monitoring of hematology, blood chemistry and urine lalues, vital signs, ECG and physical examinations, Every 3 months|pharmacogenetic analyses with blood and tumor samples from these patients, Every 3 months
This study will examine whether the new investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause ovarian, fallopian, or peritoneal cancers. Recruitment in the United States is complete but the study is still enrolling in other countries.